Calamos Wealth Management LLC Purchases 32,592 Shares of Stryker Corporation (NYSE:SYK)

Calamos Wealth Management LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3,395.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,552 shares of the medical technology company's stock after acquiring an additional 32,592 shares during the quarter. Calamos Wealth Management LLC's holdings in Stryker were worth $12,490,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital A Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $26,000. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Goodman Advisory Group LLC bought a new stake in Stryker in the 1st quarter valued at $32,000. City Holding Co. boosted its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the period. Finally, VSM Wealth Advisory LLC bought a new stake in Stryker in the 4th quarter valued at $36,000. 77.09% of the stock is currently owned by institutional investors.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

Stryker Trading Up 0.0%

Shares of SYK stock traded up $0.19 on Friday, hitting $392.00. The company had a trading volume of 536,295 shares, compared to its average volume of 1,346,875. The firm has a market cap of $149.62 billion, a P/E ratio of 52.97, a P/E/G ratio of 2.98 and a beta of 0.91. The stock's 50-day moving average is $382.39 and its two-hundred day moving average is $375.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.50 earnings per share. On average, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker's payout ratio is 45.41%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Sanford C. Bernstein set a $450.00 price target on Stryker in a research note on Monday, May 5th. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Citigroup restated a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Roth Mkm boosted their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.